The FDA’s Rare Disease Innovation Hub (Hub) has released its Strategic Agenda, detailing its first-year actions and engagement with the rare disease community while clarifying its structure and programs. The Hub fosters collaboration between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) to enhance rare disease patient outcomes. Read the Strategic Agenda here.